A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Ivosidenib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms IDIOME-STUDY
- 26 Mar 2019 Status changed from not yet recruiting to recruiting.
- 04 Jan 2019 Planned End Date changed from 1 Dec 2023 to 15 Jan 2024.
- 04 Jan 2019 Planned primary completion date changed from 1 Dec 2021 to 15 Jan 2022.